The invention generally provides improved compositions and methods for monitoring immune status of a subject. In particular, the invention provides methods for detecting BCMA in subjects to reliably monitor immune status of the subject.

The present disclosure provides a method for screening, isolating and purifying analytes.

A method is provided for treating a recipient with a biological product obtained from at least one donor that may be the same as, or different from, the recipient. The method includes identifying a targeted level of gene expression of a first gene in a biological product to be transferred from at least one donor to a recipient; treating the at least one donor to achieve the targeted level of gene expression of the first gene in the biological product; and transferring the biological product from the at least one donor to the recipient.

Systems and methods for predicting a patient response to various agents and/or combinations of agents using ex vivo dosing and imaging are disclosed. In one example, a method of determining treatment efficacy includes analyzing a solid cell culture over time, e.g., first and second responses to a solid cell culture to respective treatments may be compared to determine a treatment efficacy of each treatment. Systems and methods for applying the treatments to the cell culture and analyzing the cell culture and efficacy are disclosed.

The present invention provides a coating comprising one or more polysaccharides with binding affinity for bioanalytes, for application on the surface of a medical sampling device, wherein the one or more polysaccharides are end-point attached to the surface of the medical device, and wherein the one or more end-point attached polysaccharides have one or more polysaccharides end-point grafted to the side groups extending from their backbone. The invention also provides a process for preparing the same as well as a medical diagnostic device comprising the coating.

The invention provides methods and systems for the treatment and diagnosis of pathologic disorders by modulating a physiological state of a target biological entity via exposure of the target entity to a single or a plurality of triggered entities and for transferring of information in a non-direct way and as part of virtual reality interactive environment.

There is provided an apparatus for collecting/isolating cells from a sample including the target cells comprising: a membrane adapted to retain the target cells thereon, a first port in fluid communication with the membrane provided towards a first side of the membrane, a second port in fluid communication with the membrane provided towards a second side of the membrane, a sample container having at least one wall defining an interior space suitable to house the sample, provided on the first side of the membrane, a cell collection container provided towards the first side of the membrane, a filtrate container provided towards the second side of the membrane, a backwash fluid container provided towards the second side of the membrane, wherein the first port is movable between a first position wherein the first port is in fluid communication with the sample container, and a second position wherein the first port is in fluid communication with the cell collection container; and
wherein the second port is movable between a first position wherein the second port is in fluid communication with the filtrate container, and a second position wherein the second port is in fluid communication with the backwash fluid container.

The present invention relates to a method of diagnosing a human sepsis. The present invention further relates to a kit for diagnosing a human sepsis. The present invention also relates to a point-of-care device for performing a method of diagnosing a human sepsis. The present invention also relates to a use of a kit and/or a point-of-care device for a method of diagnosing a human sepsis. The present invention also relates to the use of a kit and/or a point-of-care device for a method of diagnosing a human sepsis. The method comprises stimulating a platelet-specific (hem-)ITAM receptor by adding a (hem-)ITAM receptor agonistic agent to a blood sample of a patient, wherein said agonistic agent comprises CRP-XL and/or convulxin, and measuring a platelet function level.

Disclosed are a composition and method for the diagnosis of diseases accompanied by impaired glucose tolerance, comprising a material for ITIH1 detection. The composition and method according to the present application enable a relatively sensitive response even to small changes in blood sugar according to various stimulants in a hyperglycemic situation as compared to glycated hemoglobin (HbA1c) which is an existing diagnostic marker widely used for patients with diabetes, which is a typical disease accompanied by impaired glucose tolerance, and thus can more precisely detect blood sugar changes under various stress situations.

The present invention relates to a method for producing an animal model of preterm birth and an animal model of preterm birth produced by the method. The animal model of the present invention can be effectively applied to investigate the causes and symptoms of preterm birth induced by cervical injury. The mortality rate of the animal model according to the present invention is low until preterm birth despite its induced preterm birth. In addition, the animal model of the present invention is produced in a higher yield than any other existing model. Furthermore, the preterm birth of the animal model according to the present invention is induced at a desired time point. Due to these advantages, the animal model of the present invention can be effectively applied to investigate the causes and mechanisms of preterm birth. The mortality rate of premature neonates born from the animal model of the present invention is considerably low and the premature neonates are immature. Therefore, the animal model of the present invention can be effectively applied to studies on complications of premature neonates.